The vaccine is being developed by researchers at the University of Pittsburgh and is the first peer-reviewed antidote. The Pittsburgh team have tested the vaccine on mice and are confident that it will be able to provide immunity for at least a year. An industrial-style production process has been used to produce the Pittsburgh Coronavirus Vaccine (PittCoVacc), meaning that once the go ahead is given, the team will be able to scale up production to deliver tens of thousands of doses per day.